FDA-approved
Digestive & weight
Lanreotide
Evidence
FDA approved
Class
Somatostatin analog
KEY TAKEAWAY
Lanreotide is a synthetic, long-acting version of somatostatin, a natural hormone that slows the release of many other hormones. It is sold as Somatuline Depot. The FDA approved lanreotide (Somatuline Depot) in 2007 for acromegaly, and later for gastroenteropancreatic neuroendocrine tumors and carcinoid syndrome.
Written by the Veylo editorial team · Updated
November 2026
What it is
Somatostatin analog
Approved for
Acromegaly and neuroendocrine tumors
Key fact
The FDA approved lanreotide (Somatuline Depot) in 2007 for acromegaly, and later for gastroenteropancreatic neuroendocrine tumors and carcinoid syndrome.
Route
Deep subcutaneous injection once a month
Evidence strength
FDA approved
Lanreotide is a synthetic, long-acting version of somatostatin, a natural hormone that slows the release of many other hormones. It is sold as Somatuline Depot.
It binds somatostatin receptors and lowers the release of growth hormone and of hormones made by certain tumors.
The FDA approved lanreotide (Somatuline Depot) in 2007 for acromegaly, and later for gastroenteropancreatic neuroendocrine tumors and carcinoid syndrome.
Acromegaly and neuroendocrine tumors.
Diarrhea, abdominal pain, gallstones and changes in blood sugar are the most common concerns.
U.S. FDA prescribing information for Lanreotide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.